Cargando…

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer

Detalles Bibliográficos
Autores principales:	Käsmann, Lukas, Taugner, Julian, Manapov, Farkhad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739220/ https://www.ncbi.nlm.nih.gov/pubmed/31534625 http://dx.doi.org/10.18632/oncotarget.27141

Ejemplares similares

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic
por: Käsmann, Lukas, et al.
Publicado: (2022)

In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer
por: Käsmann, Lukas, et al.
Publicado: (2020)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2021)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis
por: Karin, Monika, et al.
Publicado: (2020)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis
por: Eze, Chukwuka, et al.
Publicado: (2019)

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)
por: Angelini, Lucia, et al.
Publicado: (2023)

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
por: Käsmann, Lukas, et al.
Publicado: (2020)

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Gennen, Kathrin, et al.
Publicado: (2020)

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer
por: Manapov, Farkhad, et al.
Publicado: (2022)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy
por: Roengvoraphoj, Olarn, et al.
Publicado: (2020)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment
por: Monge, Chiara, et al.
Publicado: (2022)

Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer
por: Nawashiro, Ayako, et al.
Publicado: (2022)

Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature
por: Bodensohn, Raphael, et al.
Publicado: (2021)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
por: Manapov, Farkhad, et al.
Publicado: (2018)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report
por: Schiopu, Sanziana R. I., et al.
Publicado: (2021)

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study
por: Käsmann, Lukas, et al.
Publicado: (2022)

Fertility preservation in chemo-radiotherapy for rectal cancer: A combined approach
por: Mariani, S., et al.
Publicado: (2019)

High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles
por: Au, Kin Man, et al.
Publicado: (2018)

A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Lara-Velazquez, Montserrat, et al.
Publicado: (2021)

Heme Oxygenase 1‐Targeted Hybrid Nanoparticle for Chemo‐ and Immuno‐Combination Therapy in Acute Myelogenous Leukemia
por: Yong, Seok‐Beom, et al.
Publicado: (2020)

Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report
por: Manapov, Farkhad, et al.
Publicado: (2017)

Automated biological target volume delineation for radiotherapy treatment planning using FDG-PET/CT
por: Niyazi, Maximilian, et al.
Publicado: (2013)

Metachronous rectal metastasis from pulmonary adenocarcinoma after 11 years of chemo-, immuno-, and radiotherapy for recurrent lesions: a case report
por: Suzuki, Yozo, et al.
Publicado: (2019)

Commentary: Immuno-chemo-radio-therapy before esophagectomy: Our next standard?
por: Ripley, R. Taylor
Publicado: (2022)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery
por: Eze, Chukwuka, et al.
Publicado: (2020)

EMT in immuno-resistance
por: Terry, Stéphane, et al.
Publicado: (2015)

Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
por: Liu, Ya‐Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qpcqqtuj7nh47rldhddeg64uj6